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The venoms of predatory marine snails (Conus spp.) contain
diverse mixtures of peptide toxins with high potency and selec-
tivity for a variety of voltage-gated and ligand-gated ion chan-
nels. Here we describe the chemical and functional character-
ization of three novel conotoxins,D-VxXIIA,D-VxXIIB, and
D-VxXIIC, purified from the venom of Conus vexillum. Each
toxinwas observed as an11-kDaprotein byLC/MS, size exclu-
sion chromatography, andSDS-PAGE.After reduction, thepep-
tide sequences were determined by Edman degradation chemis-
try and tandemMS. Combining the sequence data together with
LC/MS and NMR data revealed that in solution these toxins are
pseudo-homodimers of paired 47–50-residue peptides. The
toxin subunits exhibited a novel arrangement of 10 conserved
cystine residues, and additional post-translational modifica-
tions contributed heterogeneity to the proteins. Binding assays
and two-electrode voltage clamp analyses showed that
D-VxXIIA, D-VxXIIB, and D-VxXIIC are potent inhibitors
of nicotinic acetylcholine receptors (nAChRs) with selectivity
for 7 and 2 containing neuronal nAChR subtypes. These
dimeric conotoxins represent a fifth and highly divergent struc-
tural class of conotoxins targeting nAChRs.
Nicotinic acetylcholine receptors (nAChRs)4 belong to the
Cys-loop superfamily of pentameric ligand-gated ion channels.
Neuronal nAChRs are generally formed from a combination of
 and  subunits (2–10 and 2–4) that can assemble into a
diversity of nAChR subtypes with different pharmacological
and functional properties (1). Given their physiological impor-
tance, nAChRs are often targeted by venom peptides (2).
Our current knowledge of the structure and function of
nAChRs owes much to studies using snake toxins as biochem-
ical or pharmacological tools to isolate and characterize this
receptor (3). The “bungarotoxin” family of proteins in the
venom of elapid and hydrophid snakes includes the - and
-neurotoxins, muscarinic toxins, cytotoxins, cardiotoxins,
fasciculins, calciseptins, and mambins (4, 5). The structurally
related short-chain and long-chain -neurotoxins and the
“weak non-conventional” snake toxins are comprised of
60–74 amino acids, including 8 or 10 cystine residues and
their structures have a three-fingered fold. The - and
-neurotoxins both inhibit nAChRs but differ in their spec-
ificity and binding kinetics (4).
Conotoxins are small disulfide-rich peptide toxins found
in the venom of predatory marine snails from the genus
Conus. These venom peptides generally target a variety of
voltage-gated and ligand-gated ion channels (6, 7). Conotox-
ins acting at nAChRs include the -conotoxin, A-cono-
toxin, -conotoxin, and S-conotoxin families. The -cono-
toxins are a large family of well characterized competitive
nAChR antagonists with diverse subtype selectivities that
allow the pharmacological dissection of nAChR subtypes (1,
8). The structurally different A-conotoxins are competitive
antagonists with specificity for muscle nAChRs but lack the
selectivity for the 1/ interface that is exhibited by the 3/5
subfamily of -conotoxins (7), whereas the -conotoxins are
non-competitive antagonists at the muscle nAChR subtype
(7). The recently described S-conotoxin RVIIIA is a nAChR
antagonist with broad subtype activity and a preference for
the muscle subtype (9). Despite the importance of these tox-
ins for prey capture, not all species of cone snails possess
detectable levels of all four of these classes of nAChR antag-
onists in their venom. For example, no toxins from these
families have previously been described from the venom of
Conus vexillum. It has been suggested that different clades of
Conus species might utilize unique conotoxin families for
particular purposes (10–12).
Post-translationalmodifications contribute to the rich diver-
sity and heterogeneity of conotoxins (13, 14) and may confer
unique structural and functional traits. Examples of post-trans-
lational modifications in conotoxins include proline hydroxy-
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lation and glutamic acid -carboxylation as in GID (15), tyro-
sine sulfation as in EpI (16), and disulfide bonds and COOH-
terminal amidation in most conotoxins. The only multimeric
protein described so far fromConus venoms is a phospholipase
(17). In contrast, there are numerous examples of heterodimers
among venom toxins from several other genera including ants,
spiders, scorpions, and snakes (17–23). Additionally, -neuro-
toxins from snake venom can form homodimers in solution at
physiological concentrations, raising implications for both the
mechanism of polypeptide chain folding during biosynthesis of
the toxins and for their interaction with nAChRs (4).
Neuronal nAChRs are of increasing interest in human
medicine as therapeutic targets for the treatment of chronic
pain and neurological disorders such as Alzheimer and Par-
kinson diseases (24, 25). To decipher the functions and loca-
tions of the different nAChR subtypes, additional subtype-
specific ligands are required. Cone snail venoms have been a
particularly rich source of new inhibitors of nAChRs. This
study describes the discovery and characterization of three
novel post-translationally modified conotoxins, VxXIIA,
VxXIIB, and VxXIIC, which occur as dimers and produce
a slowly reversing block of 7 and 32 nAChRs. These
D-conotoxins contribute to our growing knowledge of
ligands interacting at nAChRs.
EXPERIMENTAL PROCEDURES
Crude Venom Extraction—Specimens of C. vexillum (8),
Conus mustelinus (7), Conus miles (9), and Conus capitaneus
(10) were collected from the Great Barrier Reef, Australia.
Crude extracts were prepared from venom duct material using
30% acetonitrile/water acidified with 0.1% trifluoroacetic acid.
Soluble material was lyophilized and stored at 20 °C prior to
use. The crude venom samples were tested for their ability to
inhibit agonist-evoked currents of 7 and 32 nAChRs
expressed in Xenopus laevis oocytes (see below).
Crude Venom Enrichment—A portion of each crude venom
extract (10 mg) was fractionated by size-exclusion chromatog-
raphy (Superdex Peptide, HR 10/30, AmershamBiosciences) to
generate two fractions containing peptides and proteins in the
size ranges 5–15 and 0.5–5 kDa. The column was eluted with
30% acetonitrile, 0.048% trifluoroacetic acid, aqueous at a flow
rate of 0.5 ml/min, with detection at 214 nm. Only the 5–15-
kDa fraction of each species inhibited oocyte-expressed 7
nAChRs.
Purification of Proteins—To isolate the 5–15-kDa compo-
nents active at the nAChR, a portion of the crude venomextract
(10mg)was fractionated by semi-preparative RP-HPLC (10m
C18, Vydac) eluted at 3ml/min with a linear gradient of 0–90%
solvent B over 80 min, using a Waters 600 solvent delivery sys-
tem (A, 0.1% aqueous trifluoroacetic acid; B, 90% acetonitrile/
0.09% aqueous trifluoroacetic acid). Each species contained
11-kDa proteins that inhibited 7 and 32 nAChRs. The
active fractions from C. vexillum were further purified by ana-
lytical C18 RP-HPLC using 5-m 4.6  250-mm Jupiter and
Vydac columns eluted at 1 ml/min, or a 3.5-m 300 SB-C18
2.1 150-mm Zorbax column eluted at 0.18 ml/min using 0.5
or 1% linear gradients from 0 to 50% B over 45 min at 65 or
23 °C. The activity of each of the three 11-kDa proteins iso-
lated from C. vexillum venom was confirmed by retesting the
purified material on oocyte-expressed nAChRs and an AChBP
binding assay.
LC/MSAnalyses—LC/MS analysis of crude venom extract or
a partly purified mixture of dimeric toxins was undertaken
using an Applied Biosystems/MDS SCIEXQSTAR Pulsar elec-
trospray ionization quadrupole time-of-flight (ESI QqTOF)
mass spectrometer equipped with an electrospray ionization
source and linked to an upstream Agilent 1100 Series HPLC
system. LC was performed with a Zorbax C3, 2.1  150-mm
5-m RP-HPLC column eluted with 0–60% B for 60 min (A
0.1% formic acid, B 90% acetonitrile, 0.09% formic acid), at 180
l/min and a temperature of 23 or 65 °C. Time of flight-MS
scans were run in positive ion mode over a mass range of 500–
2200 atomic mass units with an ion spray voltage of 5300 V. A
positive mode “hi/lo” declustering LC/MS experiment as
described previously (26) was conducted for additional verifi-
cation of -carboxyglutamic acid residues. Data processing of
LC/MS data were performed using the software package Bio-
analyst (PE-Sciex, Canada). Apexmass is defined as themass of
the isotope distribution at maximum intensity as identified by
the mass reconstruction tool in the Bioanalyst software.
Electrophoresis—Samples were solubilized in 8 M urea, 4%
CHAPS, and loaded onto IPG strips (Immobilin Dry Strips pH
6–11, 7 cm, Amersham Biosciences) using passive hydration.
SDS-PAGE was run with either 16% polyacrylamide or Novex
precast 10–20% Tricine mini-gels under standard non-reduc-
ing conditions. Gels were either stainedwith colloidal Coomas-
sie Blue G-250 or proteins were transferred to polyvinylidene
difluoride using SDS/glycine buffers and then stained with
Coomassie Blue.
Reduction and Alkylation of Cystine Residues—The purified
11-kDa proteins (20 pmol) were reduced in the presence of
10 mM TCEP, 50 mM ammonium acetate (pH 4.5), 10% aceto-
nitrile (37 °C for 1 h) and subsequently alkylated in the added
presence of 20 mM maleimide (37 °C for 1 h). The alkylated
peptides were repurified by RP-HPLC.
ProteolyticDigestion—Samples of reduced and alkylated pep-
tides from C. vexillum were subjected to digestion with the
proteolytic enzymes pepsin, trypsin (Sigma), or endoproteinase
Arg-C (sequencing grade, Roche). Briefly, for pepsin digestion,
100 g of reduced and alkylated peptide was suspended in
100 l of a solution containing 50 mM formic and 50 mM acetic
acid to which 2 l of a 1 mg/ml stock solution of pepsin was
added, and the reaction mixture was incubated for 3 h at 37 °C.
Digestion was terminated by storage at 20 °C. For trypsin
digestion, 100 g of reduced and alkylated peptide was sus-
pended in 100l of 100mMammoniumbicarbonate (pH7.3) to
which 2l of a 1mg/ml stock solution of trypsinwas added, and
the reaction mixture incubated for 3 h at 37 °C. Digestion was
terminated by addition of an equal volume of 0.1% trifluoroace-
tic acid (aqueous) and storage at 20 °C. Endoproteinase
Arg-Cdigestionwas achieved by dissolving100g of reduced
and alkylated peptide in an incubation buffer of 100 mM Tris-
HCl, 10 mM CaCl2 (pH 7.6) to which 5 l of an 0.1 mg/ml
enzyme solution and 10 l of activation solution (50 mM dithi-
othreitol, 5 mM EDTA) was added and allowed to incubate for
3 h at 37 °C. The resulting fragments from proteolytic diges-
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tions were purified by analytical RP-HPLC and analyzed by
Edman sequence chemistry as well asMS andMS/MSmethods
as described below.
Sequencing by Edman Chemistry—Edman NH2-terminal
sequence analysis was undertaken on purified material with
disulfide bonds intact or with cysteine residues alkylated with
maleimide after reduction with TCEP, as described above.
Fragments generated by proteolytic digest reactions were sim-
ilarly sequenced with an Applied Biosystems Procise Protein
Sequencer (HT or 492cLC models).
Sequence Determination by MS/MS Analyses of Peptide
Fragments—Tandem MS (MS/MS) experiments were con-
ducted using the QSTAR. Samples in 20–50% aqueous aceto-
nitrile, 0.1% formic acid were continuously infused into the ion
source at 40 l/min in a carrier of 70% eluent B (90% acetoni-
trile, 0.05% formic acid). Data were acquired over 400–2000
atomic mass units for 5–10 min with an ion spray voltage of
9500 V and collision energy of 10–60 V, as required.
Additional MS Experiments—An ES-MS pH titration exper-
iment was conducted using solvents containing60% acetoni-
trile and either 1% trifluoroacetic acid, 0.05% formic acid, 0.05%
acetic acid, 20 mM ammonium acetate, or 20 mM ammonium
bicarbonate to cover the pH range 1–9 in one pH unit incre-
ments. Samples of the 11-kDa proteins in these solutions
were introduced into the QSTAR by infusion at low flow rates
and analysis performed as described above. A voltage step
experiment was conducted to assess stability of the dimer asso-
ciation by application of stepwise increases in sample cone volt-
age (10–70 V) in parallel with extraction cone voltage (4–25 V)
and a capillary voltage of 3500 V using anMicromass LCT ESI-
TOF instrument.
Protein Quantitation—Crude venom extract was quanti-
tated by BCA protein assay. VxXIIA was quantified initially
by triplicate amino acid analysis, and used as an internal
standard for quantitation of the other proteins. An extinc-
tion coefficient adjustment factor was determined for each
protein (27) and used to adjust HPLC peak area to quantify
VxXIIB and VxXIIC.
1H NMR Spectroscopy—All NMR experiments were re-
corded on a Bruker Avance 600 spectrometer equipped with an
x,y,z gradient unit. Protein concentration was 1 mM. Native
VxXIIA was examined in 90% H2O, 10% D2O (pH 3.0), at tem-
peratures ranging from 280 to 313 K and in 100% D2O (298 K).
1H NMR experiments recorded were NOESY (28, 29), with
mixing time of 300 ms, TOCSY (30) with a mixing time of 80
ms, and TOCSY and NOESY in 100% D2O (31). All spectra
were run over 7184 Hz (600 MHz) with 4 K data points, 256–
512 free induction decays, 8–80 scans, and a recycle delay of 2 s.
The solvent was suppressed using WATERGATE (32). Slowly
exchanging amides were detected by dissolving protein in D2O
and recording a series of one-dimensional and TOCSY spectra
at 298 K. Amide protons remaining after 24 h were classified
as slowly exchanging. Spectra were processed using XWIN
NMR and Aurelia, and subtraction of background was used
to minimize T1 noise. Chemical shift values of VxXIIA were
referenced internally to sodium 2,2-dimethyl-2-silapentane-
5-sulfonate (DSS) at 0.00 ppm. The protein was assigned
using the “sequential walk” (33). Secondary H shifts were
measured and compared with random coil shift values (34).
Expression of nAChRs in Xenopus Oocytes—RNA prepara-
tion, oocyte preparation, and expression of nAChRs inXenopus
oocytes were performed as described previously (15, 26).
Briefly, plasmids containing cDNA encoding rat 3, 4, 7, 2,
and 4 nAChR subunits (kindly provided by J. Patrick, Baylor
College of Medicine, Houston, TX) were subcloned into the
oocyte expression vector pNKS2 (35). cDNAs for the rat1,1,
, and  subunits of themuscle nAChRwere provided by Dr. V.
Witzemann (Max-Planck Institute for Medical Research).
Oocytes were injected with 50 nl of cRNA (5–50 ng/l), and
kept at 19 °C in ND96 (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1
mMMgCl2, and 5 mM HEPES at pH 7.4) supplemented with 50
mg/liter of gentamycin (Sigma).
Two-electrode Voltage Clamp Recordings—Two-electrode
voltage clamp recordings at a holding potential of70mVwere
performed in oocytes 1–10 days after cRNA injection. Assays
were conducted using a custom-made manifold for rapid solu-
tion exchange (300 ms) and a 50-l funnel-shaped oocyte
chamber as described previously (15) or an automated OpusX-
pressTM 6000A work station (Axon Instruments Inc., Union
City, CA). 100 M ACh (Sigma) was used to activate 32,
34, 44, and 42 combinations, 1 M ACh was used to
activate 11 nAChRs and 100 M nicotine (Sigma) was
used to activate the 7 nAChRs. Agonist pulses were applied in
2-s pulses at 4- or 5-min intervals until consistent control
responses were obtained. A 5.5-l aliquot of a 10-fold con-
centrated toxin solution was added directly into the static
bath, to conserve material and avoid potential losses of the
toxin to tubing surfaces. Each concentration was tested on at
least three different oocytes from two separate batches. Esti-
mates of potency were obtained by fitting concentration-
response curves to the data by the equation: % response 
100/{1  ([toxin]/IC50)nH} using Prism software (GraphPad
version 3.0, San Diego, CA). The IC50 values were considered
significantly different if the 95% confidence intervals did not
overlap.
AChBP Binding Assay—Purified recombinant AChBP with a
histidine tag was kindly provided by Titia Sixma and Angus
Smit (Netherlands Cancer Institute and Vrije University,
respectively, The Netherlands). An AChBP binding assay was
performed according to the procedure of Smit et al. (36).
Briefly, toxins were dried and resuspended in 85 l of binding
buffer (phosphate-buffered saline, 0.5 mg/ml bovine serum
albumin, 0.1% Tween 20 (pH 7.4), plus 10 l of AChBP (0.2
ng/l) (7), 10 l of 125I-bungarotoxin (125I-BgTx), (Amersham
Biosciences), and 20l TALONmetal affinity resin (Clontech).
Assays were incubated for 1 h at 23 °C and filtered throughGFB
filters using a Millipore manifold and a wash buffer of 20 mM
HEPES and 125 mM NaCl (pH 7.2). Retained radioactivity on
the filters was measured using a -counter (Wallac). Specific
binding was determined by subtraction of nonspecific bind-
ing determined in the presence of 80 M tubocurarine
(Sigma). (Similar results were obtained with 3.2 M -BgTx
(Sigma).) A saturation binding experiment was conducted by
measuring specific 125I-BgTx binding in the absence or pres-
ence of toxin at a concentration of twice the toxin IC50. 125I-
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BgTx was added over the concentration range 0.5–75 nM.
Nonlinear regressions were fitted to each experiment with
Prism software (GraphPad).
RESULTS
Protein Identification—Initial analyses of the crude venom
from several vermivorous cone snail species indicated the pres-
ence of a number of11-kDa proteins with inhibitory activity
at 7 and 32 nAChRs (data not shown). Comparing the MS
of intact and reduced material revealed that these proteins in
C.mustelinus,C.miles,C. capitaneus, andC. vexillum occurred
as dimers of two peptide subunits. The crude venom of C. vex-
illum was the least complex, containing three dominant and
apparently homogeneous proteins of 10,300–11,400Da (Fig. 1)
that we namedVxXIIA, VxXIIB, and VxXIIC. Each protein was
purified to a single peak byRP-HPLC, however, varying levels of
micro-heterogeneity were revealed by LC/MS analysis of crude
venom (Fig. 1). The reduced subunits were half the size of the
FIGURE1.LC/MSofC. vexillum crudevenom.A, the total ion current (TIC ) showsnativeVxXIIA, VxXIIB, andVxXIICmarked 1, 2, and 3, respectively. AC. vexillum
shell is shown in the inset. B, i–iii, ion spectra from the three peptides in the crude venom are shown. C, i–iii, ion spectra from the three semi-purified peptides
are shown.D, i–iii, deconvoluted/reconstructedmass spectra for the three peptides are shownwithmaximum ions andmass values labeled. The averagemass
values for components in the crude venom were10,270 Da for VxXIIA,11,472 Da for VxXIIB, and10,553 Da for VxXIIC. The VxXIIB spectra included ions
consistent with a monomer mass at5,735 Da.
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11-kDa native toxins and for C. vexillum ranged in monoiso-
topic mass from 5135–5741 Da (Fig. 2, Table 1). SDS-PAGE of
the native proteins indicated an apparent size of 10–12 kDa
(data not shown), supporting the conclusion from SE-HPLC
and MS data that the proteins occur as dimers. The LC/MS
analysis of crude venom also detected ions for minor monomer
forms of VxXIIB, whereas VxXIIA andVxXIIC occurred exclu-
sively as dimers (Fig. 1).
MS analysis at raised voltages and LC/MS at raised temper-
ature (65 °C) failed to disrupt the dimers (data not shown). The
higher temperature improvedHPLC separation of components
from the heterogeneous mixtures but promoted decarboxyla-
tion of putative -carboxyglutamic acid residues in VxXIIB, as
indicated by amass shift of44Da (data not shown). ESI-MSof
native VxXIIB over pH 1–9 revealed no discernible shift from
dimer to monomer at conditions up to pH 5, but beyond that
pH neither the dimer nor monomer could be detected. MS
analyses showed that the dimer remained intact following
denaturation treatments with urea, guanidine HCl, or 50% tri-
fluoroethanol (data not shown).
Determination of Primary Sequences—Sequence information
obtained directly from EdmanN-terminal sequence analyses of
the reduced and alkylated peptides was limited, due in part to
rapid losses in successive cycles of Edman chemistry despite
adequate initial yields. As a result, an unambiguous sequence
assignment of the full-length peptide could be made for only
the first 15–20 cycles. Proteolytic digests with trypsin and pep-
sin, or endoproteinase Arg-C and pepsin, were used to generate
nested sets of overlapping peptide fragments from each precur-
sor peptide. Sequence information deduced from peptide frag-
ments by MS/MS was used to complete the sequences sug-
gested by Edman N-terminal sequencing data in some cases,
and for de novo sequence determination in other cases. The
resulting peptide sequences (Table 1) had 43% homology,
sharing 21 of the 47–50 residues including a conserved
WGRCC motif. The determined monoisotopic molecular
masses of the reduced peptides, together with the sequence
data, suggested that the three peptides VxXIIA, VxXIIB, and
VxXIIC all had a free carboxyl terminus (Table 1).
The Edman NH2-terminal sequences of several 11-kDa
nAChR antagonists from C. mustelinus, C. miles, and C. capi-
taneus gave a consensus sequence DXXXCQXXTOG-
SKWGRCC (X indicates sequence variation) that corresponded
to the NH2 terminus of VxXIIA, indicating these species also
produce D-conotoxins. The observed apex mass values of the
11-kDa proteins from these species ranged from 10,840 to
10,940 Da for C. mustelinus, 10,280 Da for C. miles, and
10,990 to 11,000 Da for C. capitaneus. As seen for C. vexillum,
upon reduction each protein separated into peptides of half the
size of the native protein.
Post-translational Modifications—The ion spectrum for
native VxXIIA revealed apex mass values of10,255,10,271,
and 10,287Da (Fig. 1). This ion series reflected differences of 16
mass units that could be attributable to hydroxyproline/proline
heterogeneity or perhaps to partial methionine oxidation. A
minor ion series with differences of 112 mass units probably
reflected the presence of trifluoroacetic acid adducts. Upon
reduction, intact VxXIIA (Fig. 2A) gave rise to two closely elut-
ing peaks present in a 1:1 ratio (Fig. 2B). The ion spectrum (m/z)
for the first eluting peak of reduced VxXIIA had a monisotopic
mass of 5150 Da, whereas the second peak had a monoisotopic
mass of 5134Da (Fig. 2). An expanded view of the 9 ion for the
intact protein of VxXIIA revealed that the three co-eluting
components exist in a 1:2:1 ratio (Fig. 2A, inset). These data are
FIGURE 2. LC/MS of VxXIIA. A, the total ion current (TIC ) for intact VxXIIA is
shownwith the corresponding ion spectra shown in the inset. B, the total ion
current for reduced VxXIIA shows two components. C, the ion spectra from
peak1of reducedVxXIIA (mass 5150Da,monoisotopic value), and thedecon-
voluted mass spectrum, inset, are shown. D, ion spectra from peak 2 of
reduced VxXIIA (mass 5134 Da, monoisotopic value) and the deconvoluted
mass spectrum, inset, are shown.
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consistent with dimers composed of two subunits containing
either a proline or hydroxyproline in a 1:1 ratio. MS also
revealed the presence of additional minor variants consistent
with both more and less frequent hydroxyproline substitution
(data not shown).
The sequence obtained for VxXIIA (Table 1) was consistent
with the observed monoisotopic mass value of 5134.6 Da for
one of the two reduced subunits (Fig. 2, Peak 2). An equally
abundant variant, [Hyp29]VxXIIA, was identified by sequenc-
ing and explained the second observed monoisotopic value of
5150.6 Da seen for the first eluting peak (Fig. 2). Additionally
the minor variants [Hyp25,Hyp29]VxXIIA and [Pro10]VxXIIA
were identified. Thus the observed mass values for the three
major components of the native VxXIIA complex, 10,255,
10,271, and 10,287 Da (apex values), corresponded to a
homodimer of VxXIIA, a pseudo-homodimer of both VxXIIA
and [Hyp29]VxXIIA, and a homodimer of [Hyp29]VxXIIA.
These three components occurred in a 1:2:1 ratio consistent
with the random association of two different subunits of equiv-
alent abundance as suggested above. Their predicted average
mass values are 10,255.76, 10,271.76, and 10,287.76 Da,
respectively.
VxXIIB also purified to a single peak by RP-HPLC but again
LC/MS analysis revealed microheterogeneity. The major form
had a mass of 11,472 Da and there was another component
with a mass deficit of58 Da. Additional minor variants, con-
sistentwith hydroxyproline/proline substitution ormethionine
oxidation, were also observed. Further heterogeneity was
attributable to decarboxylation of -carboxyglutamic acid res-
idues. It is not known if the differently decarboxylated forms are
natural variants or arose from sample degradation. Chromatog-
raphy ofVxXIIB after reduction revealed one dominant peak, in
contrast to the two peaks observed for VxXIIA. The observed
monoisotopic mass of the major form of reduced VxXIIB was
5,741 Da.
A single dominant VxXIIB sequencewas identified (Table 1).
A minor [des-Gly50]VxXIIB variant with a likely amidated
COOH terminus was determined by MS/MS. MS of NH2-ter-
minal peptic fragments of VxXIIB indicated the presence of a
further minor variant [Hyp14]VxXIIB (data not shown). These
variants were consistent withmass data from the nativeVxXIIB
sample, with observed apex mass values of 11,472, 11,414,
and 11,488 Da (Fig. 1). The corresponding predicted average
mass values were 11,470.88, 11,412.88, and 11,486.88 Da.
Standard Edman chemistry analysis of intact VxXIIB showed
low levels of glutamate in positions three and five, indicative of
-carboxyglutamic acid residues at those locations. However,
the results of multiple sequence analyses were ambiguous, with
varying levels of glutamate in those cycles. MS analysis of the
intact peptide and NH2-terminal fragments showed mass val-
ues that fitted a sequence containing two -carboxyglutamic
acid residues (data not shown). It also showed the presence of
components with mass values44 and88, indicating partial
decarboxylation of -carboxyglutamic acid, typically observed
for conotoxins containing this residue. The second of the two
putative -carboxyglutamic acid residues did not readily decar-
boxylate in MS, even at elevated voltage settings (data not
shown). Heat treatments (65 °C for 1 h prior to LC/MS, or
LC/MS at 65 °C) predictably resulted in increased -carboxy-
glutamic acid decarboxylation, with decarboxylated VxXIIB
eluting earlier than the fully carboxylated form. TandemMS of
an NH2-terminal pepsin-cleaved fragment 1-23 (mass 3121),
also showed a loss of 88 Da, again consistent with the presence
of two -carboxyglutamic acid residues in the sequence.
VxXIIC was also purified to a sharp single peak by RP-HPLC
analysis and LC/MS analysis showed little evidence of hetero-
geneity, except for a minor form with a mass consistent with
either a proline/hydroxyproline substitution or methionine
oxidation. Themajor form had amass of10,553Da. Chroma-
tography of VxXIIC after reduction revealed one dominant
TABLE 1
Comparison of deduced sequences for C. vexillum components VxXIIA, VxXIIB, and VxXIIC
The sequences were derived from intact material by Edman chemistry, and from fragments generated by enzyme digestions, by both Edman chemistry and MS/MS.
Residues shown underlined were determined by MS/MS, either by revision from Edman data or by de novo sequencing. Other residues were determined by Edman
sequencing and confirmed byMS andMS/MS. J denotes residues likely to be -carboxyglutamic acid, O denotes hydroxyproline, and gaps are for sequence alignment. Sites
of potential Pro/Hyp substitution between variants of a peptide are shadowed. Cystine residues are highlighted in bold. Residues or motifs conserved between all three
peptides are indicated. The mass values are consistent with all three peptides having a free carboxyl terminus.
1 Mass values given for the reduced monomers are monoisotopic values.
2 Mass values for native dimers are given as observed maximum or apex mass values, and predicted (calculated) average values because the monoisotopic values could not be
determined with confidence for components in that mass range.
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peak in contrast to the two peaks observed for VxXIIA. The
observed monoisotopic mass of the major form of reduced
VxXIIC was 5,282 Da. The sequence of VxXIIC (Table 1) was
determined largely from MS/MS of fragments generated from
trypsin and pepsin digests, in addition to the partial NH2-ter-
minal sequence obtained using Edman chemistry data. Aminor
variant [Hyp10]VxXIIC was determined by MS/MS. The
observed apex mass values 10,553, 10,569.4, and 10,585.4 Da
corresponded to the predicted average mass values (assuming
an additional hydroxyproline substitution in one subunit vari-
ant) of 10,552.18, 10,568.18, and 10,584.18 Da, respectively.
The D-conotoxins showed marked increases in hydropho-
bicity after reduction, reflected by 4–9-min delays in elution
time on RP-HPLC (data not shown). This was particularly
apparent for VxXIIB and suggests that substantial shielding of
hydrophobic residues occurs in the native toxins. Two-dimen-
sional gel electrophoresis of VxXIIA showed that the protein
had a pI of 10 (data not shown) consistent with VxXIIA,
VxXIIB, andVxXIIC containing five to seven basic residues (see
Table 1). Interestingly, there was no MS evidence of het-
erodimers with mass values corresponding to mixtures of
VxXIIA and VxXIIB, VxXIIA, and VxXIIC, or VxXIIB and
VxXIIC.
Activity Assay of Crude Venom—C. vexillum crude venom
was screened for its ability to inhibit agonist-evoked currents of
different combinations of rat neuronal nAChR subunits (32,
34, 42, 44, and 7) heterologously expressed in Xeno-
pus oocytes. Crude venom (50 g of protein/ml) caused 100%
block of both the 32 and 7 nAChR subtypes, and 69% block
of the 42 subtype (data not shown). No significant activity
was detected at the 44 or 34 subtypes. Assay at the 32
nAChR of fractions generated by size-exclusion chromatogra-
phy of the crude venom indicated the presence of active com-
ponents in the 5–15-kDa fraction (data not shown). Surpris-
ingly, no activity was detected in the small peptide fraction
where -conotoxins typically elute. The other species investi-
FIGURE3.NativeVxXIIA,VxXIIB, andVxXIICbinding toAChBP.A, displace-
ment of 125I-BgTx from AChBP by VxXIIA, VxXIIB, and VxXIIC (n  6 for each
data point). B, saturation binding of 125I-BgTx to AChBP in the absence (f; Kd
5.8 1.6 nM, Bmax 39,300 2,800 cpm) or presence of VxXIIB (22 nM) (; Kd
3.2 1.5 nM, Bmax 12,200 1,200 cpm), after correction for nonspecific bind-
ing, n 2–3 for each data point.
FIGURE 4. Two-electrode voltage clamp analysis of the selectivity and
potency of native VxXIIA, VxXIIB, and VxXIIC at oocyte-expressed rat
nAChR subunit combinations. Xenopus oocytes were clamped at 70 mV
and responses to 2-s pulses of 100 M ACh were recorded after a 3-min pre-
incubation with the indicated toxin. A, comparison of the activity of VxXIIA,
VxXIIB, and VxXIIC at 32 (300 nM peptide), 7 (3 nM peptide), 42 (3 M
peptide) nAChRs, andmuscle (3Mpeptide) nAChR subunit combinations. B,
concentration-response analyses for VxXIIB at oocyte-expressed nAChR sub-
unit combinations. IC50 values andHill slopes are given in Table 2. Eachmean
represents the average of measurements from at least three different
oocytes. Error bars represent S.E.
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gated in this study showed a similar activity profile (see “Exper-
imental Procedures”).
Characterization of Activity of Purified Proteins—Analysis of
the inhibition of 125I-BgTx binding to AChBP by VxXII pro-
teins indicated a rank order of potency of B C A with IC50
values of 27M for VxXIIA (Hill slope0.94), 11 nM (Hill slope
of 1.19) for VxXIIB, and 3 M for VxXIIC (Hill slope 1.32)
(Fig. 3A). Saturation binding experiments with 125I-BgTx in the
presence of 22 nM VxXIIB revealed a significant, non-sur-
mountable reduction of 125I-BgTx binding to AChBP by
VxXIIB (Fig. 3B).
To establish nAChR subtype selectivity, VxXIIA, -B, and -C
were tested for inhibition of agonist-evoked responses on four
oocyte-expressed receptor subunit combinations (Fig. 4A). All
three D-conotoxins showed selectivity for 7 and 32
nAChRs, with VxXIIB being the most potent toxin on all sub-
unit combinations. The rank orders of potency were BAC
at 7 and 32 subtypes and B  C  A at 42 and muscle
subtypes.
For a more detailed functional characterization of the subtype
selectivity of VxXIIB, concentration-response relationships were
determined at oocyte-expressed
32, 7, 42, and muscle subunit
combinations (Table 2, Fig. 4B).
VxXIIB had low nanomolar potency
at32nAChRs (IC50 8.4 nM) and7
receptors (IC50 0.4 nM), modest affin-
ity at the 42 (IC50 0.23 M) and
muscle subtypes (IC50 3.5 M), and
little activity at 4 containing recep-
tors at concentrations up to 3 M
(Table 2, Fig. 4B). The concentration-
response analysis of VxXIIA at 32
nAChRs gave an IC50 of 370 nM. To
start to identifywhere these11-kDa
proteins acted on the nAChR, the
activity of VxXIIB was investigated at
two mutated nAChRs, 32 L119Q
and 32 F117A, which affect small
-conotoxin binding (37). VxXIIB
off-rates were slower at the mutant
nAChR 32 L119Q compared with
32 nAChRs (data not shown).
D-conotoxins are stable for at
least several months when stored
dry or as a 30% ACN, 0.05% tri-
fluoroacetic acid stock. However,
some dilute aqueous solutions had
reduced stability and therefore
toxin dilutions were freshly pre-
pared prior to testing.
NMR Analysis—The NOESY
spectra of VxXIIA showed well dis-
persed NH protons allowing rela-
tively straightforward assignment of
the protein. The H chemical shifts
indicated -sheet formation across
residues 14–26, with the rest of the
protein approaching a random coil
structure (Fig. 5A). Slowly exchang-
ing amides were located mainly in
the 14–26-residue region, with
Trp14, Arg16, Cys17, Leu19, Asp20,
Arg21, Cys23, Met26 as well as Gln6,
FIGURE 5.NMR studies of VxXIIA. A, secondary H chemical shift data for VxXIIA compared with random coil
chemical shift values. B, the -sheet network of VxXIIA is shown with double-headed arrows represent the
observed NOEs, and dashed lines represent H-bonds.
TABLE 2
IC50 values (nM), 95% confidence intervals (CI), and Hill slopes (nH) for
inhibition of agonist-evoked current by VxXIIB at mammalian nAChR
subunit combinations expressed in Xenopus oocytes
nAChR IC50 (95% CI) nH
7 0.4 (0.2–0.6) 1.80
32 8.4 (6.6–10.6) 0.76
42 228 (144–360) 0.68
Muscle 3460 (2800–4300) 0.99
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Tyr34, and Ser46 were present after 24 h, presumably as a result
of stabilizingH-bond interactions. Gly15 exchanged at an inter-
mediate rate and disappeared after 4.5 h. An antiparallel
-sheet structure comprising residues 13–20 (Fig. 5B) was pro-
posed after comparison of shielded amide protons with long
range NOEs. NMR analysis of VxXIIB was unproductive with
extensive heterogeneity being evident. The NMR spectrum
from VxXIIC was well dispersed and further NMR studies are
in progress.
DISCUSSION
In the search for new inhibitors of nAChRs, we isolated and
characterized three novel post-translationally modified cono-
toxins, VxXIIA, VxXIIB, and VxXIIC, from the venom of the
vermivorous cone snail C. vexillum. The toxins were found
to be novel, subtype-specific antagonists of the nAChR.
Sequences of the reduced peptides were obtained using Edman
chemistry combined with ESI-MS and tandem MS of both
intact proteins andproteolysis fragments. VxXIIA,VxXIIB, and
VxXIIC naturally occur as 11-kDa pseudo-homodimers of
paired 47–50-residue peptides (see Table 1). The peptide
monomers have a novel arrangement of 10 cystine residues that
defines a new conotoxin superfamily. These toxins contain one
or two post-translationally modified amino acids, hydroxypro-
line and -carboxyglutamic acid, which confer additional het-
erogeneity. Comparison of VxXIIA-C sequences reveals con-
served WGRCC and CSC motifs, which might be important in
the biological activity and/or the structure of these proteins, but
little homology to previously described conotoxins. Thus, the
VxXII peptides represent a novel class of conotoxins with an
unusual structure.
Native VxXIIA-C are unusually large conotoxins. Proteins
from cone snail venom include some incompletely character-
ized larger toxins and a number of enzymes and proteases rang-
ing in size from 13 to 130 kDa (7, 17, 38–44). However, the
majority of conotoxins identified so far are 1–4 kDa (45). A
small number of conotoxins of 40 residues (4.4 kDa) have
been described (see Ref. 9). These peptides contain 8 or 10
cystine residues andmostly belong to the I or S superfamilies. In
contrast to the typically small conotoxins, the toxins from ven-
oms of other animal genera are generally larger, including the
3–8-kDa spider toxins (46), the 4–9-kDa ant venom toxins
(18), and the 6–9-kDa three-finger snake toxins (3).
VxXIIA-C resemble -GVIIIA and S-RVIIIA in having 10
cystine residues, but their sequences and cystine spacing are
substantially different (see Table 3). Like S-RVIIIA, VxXIIB
has undergone a post-translational modification from a gluta-
mate to -carboxyglutamic acid at two positions. VxXIIA and a
[Hyp29]VxXIIA occur in a 1:1 ratio, which gives rise to a dis-
tinctive pattern of heterogeneity of the dimers. VxXIIB and
VxXIIC also have variants with proline to hydroxyproline sub-
stitutions for at least one site, but only as minor forms. These
toxins are antagonists of ligand-gated ion channels as is
S-RVIIIA. Teichert et al. (9) have proposed that S-superfamily
conotoxins predominantly target ligand-gated ion channels
and that some piscivores rely on S-conotoxin muscle nAChR
antagonists. The two S-superfamily representatives described
to date, -GVIIIA and S-RVIIIA, are from fish-hunting spe-
cies, whereasC. vexillum is a worm hunter. Themost widespread
peptide families targeting the nAChR, the - and A-conotoxins,
belong to theA-superfamily. Becausewedetectedno-,A-,S-,
and-conotoxins in the venom ofC. vexillum, it appears that this
species utilizes a new superfamily of toxins to target the nAChR.
Given these are dimeric toxins, we proposed that the superfamily
be named the D superfamily.
The protein dimers fromC. vexillum remained intact in high
voltage MS, size exclusion chromatography and SDS-PAGE.
Their stability was further emphasized by their resistance to
denaturating treatments and RP-HPLC at 65 °C. Exposure to
reducing conditions separated the dimer components, indicat-
ing that disulfide bonds were necessary for the dimer structure
of all three toxins. In contrast to work by Kashiwagi et al. (47)
showing that heterodimeric yeast killer toxin SMKT subunits
were non-covalently associated under acidic conditions but dis-
sociated under neutral and basic conditions, pH-dependent
dimer denaturation was not observed for the VxXII peptides.
TheVx subunit combinationswere discretewith no evidence of
heterodimers formed from intermixes of VxXIIA, VxXIIB, and
VxXIIC, indicating sequence-specific dimer formation.
The NMR analysis of VxXIIA revealed 47 resonances, in
alignment with the peptide sequence data and consistent with
the 11-kDa protein occurring as a symmetrical homodimer.
Analysis of the H chemical shifts, NOEs, and slowly exchang-
ing protons indicated that the structure contained an antipar-
allel -sheet across residues 13–20, whereas the remainder of
the protein had less well defined structure. Some residues iden-
tified as shielded from the solvent though H-bonds (Trp14,
TABLE 3
Sequence comparisons with examples of five classes of conotoxins that act at nAChRs or the 5HT3 receptors (GVIIIA)
Peptide and
familya
Cystine
residues Mass Superfamily Sequence and cystine framework Antagonism Ref.
Da
-GID 4 2184 A IRDCCSNPACRVNNOHVCb Competitive 15
A-EIVA 6 3094 A GCCGPYONAACHOCGCKVGROOYCDROSGGc Competitive 68
-PIIIF 6 2664 M GOOCCLYGSCROFOGCYNALCCRKc Non-competitive 69
S-RVIIIA 10 5167 S KCNFDKCKGTGVYNCGSCSCGLHSCRCTYNIGSMKSGCA
CICTYYb
Undefined 9
-GVIIIA 10 4189 S GCTRTCGGOKCTGTCTCTNSSKCGCRYNVHPSGBGCGCACSc 5HT3 70
D-VxXIIA 10 5134 D DVQDCQVSTOGSKWGRCCLNRVCGPMCCPASHCYCVYHR
GRGHGCSCb
Non-competitive This study
aNames include framework identifiers: I/II for -conotoxins, IV for A-conotoxins, VIII for S-conotoxins, and II for -conotoxins. The conotoxins GID, EIVA, PIIIF, RVIIIA,
GVIIIA, and VxXIIA (reduced form) are from C. geographus, C. ermineus, C. purpurascens, C. radiatus, C. geographus, and C. vexillum, respectively.
b Free carboxyl terminus (COOH), ,-carboxyglutamic acid (Gla), O-hydroxyproline (Hyp), and B, Br-Trp.
c Amidated COOH terminus (NH2).
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Arg16, Cys17, and Ser46) are in the conservedWGRCC and CSC
motifs and may thus make an important contribution to the
structure of these toxins.
Dimers have also been described from among the snake
venom -neurotoxins, -defensins, and defensin-related pep-
tides. Defensin-like structural folds and antiparallel -sheets
are contained in some toxins from platypus and scorpion ven-
oms (48, 49). Features such as hydrophobic interactions and
characteristic -sheet hydrogen bonds have been suggested to
play an important role in formation and stability of these dimers
(49–53). Similarly, features of the D-conotoxins such as the
-sheet identified in VxXIIA, and conserved motifs, might be
expected to contribute to dimer formation in these proteins.
However, the specific residues involved in dimer formation,
through either noncovalent and/or covalent interactions, have
not yet been identified.
AChBPs are homologous to the extracellular ligand-binding
domain of the nAChR, especially the7nAChR.These proteins
provide useful structural templates for modeling the ligand-
binding domain of mammalian nAChRs (54–57). Recent
AChBP co-crystallization studies have provided a detailed
insight into themolecular basis of ligand binding (58–60).Here
we tested the potency and selectivity of D-conotoxins in a
binding assay using recombinant AChBP from Lymnea stagna-
lis and by two-electrode voltage clamp analysis at different
oocyte-expressed mammalian nAChR subunit combinations.
Both approaches revealed that D-conotoxins, especially
VxXIIB, are potent antagonists at nAChRs. Purified VxXIIA,
VxXIIB, andVxXIIChad substantial activity at7- and2-con-
taining nAChRs, modest activity at the muscle subtype, and
little activity at 4-containing receptors. The rank order of
potency of VxXIIA, -B, and -C differed for 7 and 32 sub-
types (B A C) and AChBP (B C A).
A saturation binding study suggested that VxXIIB inhibited
125I--BgTx to AChBP in a non-competitive manner, indicat-
ing their binding sites on AChBP do not overlap. Initial studies
investigating D-conotoxins interactions at mammalian
nAChRs also suggests they interact with nAChRs in a different
manner to the -conotoxins. The slow recovery of the 32
nAChR from theVxXIIB blockwas enhancedwhenACh pulses
were increased from2 to 30-s durations, whereas the prolonged
presence of ACh did not influence the recovery of block from
-conotoxin MII.5 These results suggest that ACh and VxXIIB
binding sites do not overlap and that both can bind simulta-
neously to the nAChR. Substitution of 2 subunit residues
located in the cleft has been shown to influence the binding of
-conotoxins MII, PnIA, and GID, with the 2-L119Q muta-
tion strongly reducing affinity for all three -conotoxins as evi-
denced by a reduction in potency and a fast recovery from
-conotoxin block (37). In contrast, this mutation slowed the
recovery from VxXIIB block. These results suggest that the
binding sites of -conotoxins and D-conotoxins partially
overlap but thatD-conotoxin binding does not extend into the
ACh binding pocket. Interestingly, it appears that nAChR
inhibitors acting in the cleft do not need to act competitively
with ACh, perhaps because they stabilize the cleft in a confor-
mation that does not favor agonist binding.
The VxXIIA, -B, and -C are the first described members of a
new family of conotoxins that target nAChRs. Phylogenetic
analysis places C. vexillum in cone snail Clade XII (11, 12, 61)
withC. mustelinus,C. miles, andC. capitaneus, which also pos-
sessD-conotoxins withmasses of11 kDa. TheD-conotox-
ins were dominant components in the venom of C. vexillum.
Given their abundance in crude venom and variation across
species, the D-conotoxins appear to have evolved as an alter-
native strategy for prey capture for species lacking -, A-, S-,
and -conotoxins. Whereas chemical synthesis of these pro-
teins is expected to be challenging, recombinant production of
other dimeric toxins of comparable size has been achieved (49,
62–67). Co-crystallization studies with AChBP are expected to
more precisely define the structure of D-conotoxins and to
establish the molecular basis of their binding interaction at the
nAChR.
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